AmSurg (AMSG) Reports In-Line Q3 EPS, FY Rev. Guidance Tops Consensus

AmSurg (NASDAQ: AMSG) reported Q3 EPS of $1.13, in-line with the analyst estimate of $1.13. Revenue for the quarter came in at $822.2 billion versus the consensus estimate of $770.29 million.

GUIDANCE:

AmSurg sees Q4 2016 EPS of $1.23, versus the consensus of $1.28.

AmSurg sees FY2016 EPS of $4.28-$4.33, versus the consensus of $4.33. AmSurg sees FY2016 revenue of $3.15-3.17 billion, versus the consensus of $3.08 billion.

For earnings history and earnings-related data on AmSurg (AMSG) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
• FOMC minutes from July 28-29th meeting